Literature DB >> 10691916

PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: possible link with disease pathogenesis in tuberculosis.

R Hussain1, H Shiratsuchi, J J Ellner, R S Wallis.   

Abstract

Cachexia is a prominent feature of advanced tuberculosis, in association with increased expression of the monokine tumour necrosis factor (TNF)-alpha. Monocytes, have high affinity receptors (mannose, complement and Fc gamma1 and gamma111) which mediate antigen uptake and subsequent cytokine activation. Several mycobacterial proteins, including PPD, can stimulate TNF-alpha secretion from monocytes. However, the role of various receptors in stimulating or regulating TNF-alpha secretion is still unclear. We have previously shown selective augmentation of opsonic antibodies (IgG1 and IgG3) in tuberculosis patients with advanced pulmonary disease. We now analyse the role of opsonizing antibodies in modulating TNF-alpha expression in antigen stimulated monocytes. PPD was used as the prototypic mycobacterial antigen to stimulate monocytes from PPD skin test negative donors (n = 7) in the presence of plasma from tuberculosis patients (n = 8), containing known amounts of IgG1 and IgG3 anti-PPD antibodies. TNF-alpha secretion was enhanced in the presence of TB plasma (4/8) but not in the presence of control plasma. Using Spearman Rank analysis (two-tailed Fisher exact test), a significant correlation (rho = 0.762; P = 0. 04) was observed between IgG1 antibodies and enhancement of TNF-alpha secretion. No significant association was observed with IgG2 (rho = 0.310; P = 0.41), IgG3 (rho = 0.089; P = 0.81) or IgG4 (rho = - 0.357; P = 0.347) subclass antibodies. Absorption of IgG1 with protein 'A' removed the enhancement of TNF-alpha secretion activity from the plasma samples. Our results therefore indicate that IgG1 antibodies may enhance the chronic release of TNF-alpha in TB patients with progressive disease and, for the first time, show a direct link between disease pathogenesis and raised antibody levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691916      PMCID: PMC1905580          DOI: 10.1046/j.1365-2249.2000.01139.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Pulmonary tuberculosis in a BCG vaccinated area: relationship of disease severity with immunological and hematological parameters and drug resistance patterns.

Authors:  R Hussain; R Hasan; M Khurshid; A W Sturm; J J Ellner; G Dawood
Journal:  Southeast Asian J Trop Med Public Health       Date:  1996-06       Impact factor: 0.267

3.  Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins.

Authors:  H Hjelm; K Hjelm; J Sjöquist
Journal:  FEBS Lett       Date:  1972-11-15       Impact factor: 4.124

4.  IgG subclass specificity of human monocyte receptor sites.

Authors:  H Huber; S D Douglas; J Nusbacher; S Kochwa; R E Rosenfield
Journal:  Nature       Date:  1971-02-05       Impact factor: 49.962

5.  Structural studies of a human gamma 3 myeloma protein (Goe) that binds staph protein A.

Authors:  B Recht; B Frangione; E Franklin; E van Loghem
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

6.  Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors.

Authors:  L S Schlesinger
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

7.  Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients.

Authors:  R Hussain; G Dawood; N Abrar; Z Toossi; A Minai; M Dojki; J J Ellner
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

8.  In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum.

Authors:  D O Santos; P N Suffys; K Bonifácio; M A Marques; E N Sarno
Journal:  Clin Immunol Immunopathol       Date:  1993-06

9.  Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection.

Authors:  J S Friedland; J C Hartley; C G Hartley; R J Shattock; G E Griffin
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  15 in total

1.  Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis.

Authors:  R Hussain; H Shiratsuchi; M Phillips; J Ellner; R S Wallis
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Authors:  Seon-Hee Cheon; Beate Kampmann; Amy G Hise; Manijeh Phillips; Ho-Yeon Song; Katherine Landen; Qing Li; Rhonda Larkin; Jerrold J Ellner; Richard F Silver; Daniel F Hoft; Robert S Wallis
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 3.  Immunoregulation in TB: observations and implications.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

4.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis.

Authors:  D N Wedlock; B Vesosky; M A Skinner; G W de Lisle; I M Orme; B M Buddle
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis.

Authors:  Michael D Welsh; Rodat T Cunningham; David M Corbett; R Martyn Girvin; James McNair; Robin A Skuce; David G Bryson; John M Pollock
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

7.  Modulation of immune responses to Mycobacterium bovis in cattle depleted of WC1(+) gamma delta T cells.

Authors:  Hilary E Kennedy; Michael D Welsh; David G Bryson; Joseph P Cassidy; Fiona I Forster; Christopher J Howard; Robert A Collins; John M Pollock
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

8.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

9.  Monocytes and neutrophils from tuberculosis patients are insensitive to anti-inflammatory effects triggered by the prototypic formyl peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP).

Authors:  M Beigier-Bompadre; M Alemán; P Barrionuevo; M C Franco; C J Rubel; M Del C Sasiain; M S Palermo; E Abbate; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens.

Authors:  Gilson C Macedo; Adriana Bozzi; Helena Rachel Weinreich; Andre Bafica; Henrique C Teixeira; Sergio C Oliveira
Journal:  Clin Dev Immunol       Date:  2010-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.